uploads///Analysts Recommendations

Analysts’ Recommendations for United Therapeutics in March 2018

By

Updated

Recent developments

In January 2018, United Therapeutics (UTHR) and Corsair Pharma entered into a strategic collaboration agreement for Corsair Pharma’s portfolio of treprostinil products and equity investments by United Therapeutics in Corsair Pharma.

According to the terms of the agreement, United Therapeutics received an exclusive license to Corsair Pharma’s intellectual property for the development of treprostinil prodrugs for the treatment of individuals with pulmonary arterial hypertension (or PAH).

The strategic collaboration agreement between the two companies is expected to support United Therapeutics’ RemoPro. RemoPro was developed to allow subcutaneous treprostinil therapy in PAH patients.

Article continues below advertisement

Analysts’ recommendations

Thirteen analysts were tracking United Therapeutics in March 2018. Two analysts recommended a “strong buy,” and none of the analysts recommended a “buy.” Six analysts recommended a “hold,” four analysts recommended a “sell,” and one analyst recommended a “strong buy.”

On March 29, 2018, United Therapeutics had a consensus 12-month target price of $126.17, which represented an ~14.2% return on investment over the next 12 months.

Peers’ ratings

Of the 21 analysts tracking Incyte (INCY) in March 2018, ~81.0% of these analysts recommended some form of a “buy.” On March 29, Incyte had a consensus 12-month target price of $141.33, which represented an ~66.4% return on investment over the next 12 months.

Of the 16 analysts tracking Alnylam Pharmaceuticals (ALNY) in March 2018, ~81.0% of these analysts recommended some form of a “buy” rating. On March 29, Alnylam Pharmaceuticals had a consensus 12-month target price of $157.88, which represented an ~21.6% return on investment over the next 12 months.

Of the nine analysts tracking Nektar Therapeutics (NKTR) in March 2018, four analysts recommended a “strong buy,” four analysts recommended a “buy” rating, and one analyst recommended a “hold.” On March 29, Nektar Therapeutics had a consensus 12-month target price of $91.57, which represents a 12.8% decline over the next 12 months.

Advertisement

More From Market Realist